Angiotensin-(1-12)/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human

Santiago Reyes1, Che Ping Cheng2, Drew J Roberts1

  • 1Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Abstract

Insights

This study shows that the Angiotensin-(1-12)/chymase pathway activates cardiac L-type calcium currents. This intracrine renin-angiotensin system (RAS) activation in cardiomyocytes may contribute to hypertension and cardiac hypertrophy.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Renin-Angiotensin System Research

Background:

  • Non-canonical, renin-independent mechanisms for angiotensin II (Ang II) biosynthesis are increasingly implicated in human pathologies.
  • Direct Ang II generation from angiotensin-(1-12) [Ang-(1-12)] by chymase is a critical intracrine pathway for cardiac function regulation.

Purpose of the Study:

  • To investigate the role of the Ang-(1-12)/chymase axis in the intracrine activation of L-type calcium currents (ICa-L).
  • To provide evidence for this pathway in a transgenic rat model with elevated cardiac Ang II levels.

Main Methods:

  • Utilized a transgenic rat model overexpressing the human angiotensinogen gene [TGR(hAGT)L1623].
  • Performed patch-clamp electrophysiology to measure ICa-L density and responses to Ang II and Ang-(1-12).
  • Employed chymase inhibitors and Ang II type 1 receptor blockers (E-3174); utilized confocal microscopy for chymase localization.

Main Results:

  • TGR(hAGT)L1623 cardiomyocytes exhibited significantly higher ICa-L density compared to Sprague Dawley controls.
  • Intracellular Ang II and Ang-(1-12) increased ICa-L in both cell types, an effect blocked by E-3174.
  • Chymase inhibition abolished Ang-(1-12)-induced ICa-L activation, and chymase was detected in cardiomyocytes.

Conclusions:

  • Demonstrated cardiomyocyte calcium channel modulation via Ang II generated by the Ang-(1-12)/chymase axis, signaling through intracellular receptors.
  • Chronic Ang II elevation in TGR(hAGT)L1623 hearts increases intracellular calcium via ICa-L.
  • This Ang-(1-12)/chymase-governed intracrine RAS activation may contribute to pathological phenotypes in hypertension and cardiac hypertrophy models.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
867
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K